Vertex Pharmaceuticals
Boston
Massachusetts
United States
774 articles with Vertex Pharmaceuticals
-
Vertex Reports Third-Quarter 2021 Financial Results
11/2/2021
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter ended September 30, 2021 and raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion.
-
Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
-
Vertex Pharmaceuticals announced positive Day 90 data from the first patient in its Phase I/II study of VX-880 in type 1 diabetes.
-
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
-
Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
9/22/2021
Vertex Pharmaceuticals Incorporated today announced its Supplement to a New Drug Submission for Pr KALYDECO ® (ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis
-
During the past two years, fundraising and investment in biotechnology have reached record levels.
-
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA(elexacaftor/tezacaftor/ivacaftor and ivacaftor)
9/17/2021
Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF).
-
Health Canada Grants Marketing Authorization for KALYDECO(ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
8/25/2021
Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for PrKALYDECO®
-
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
-
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
-
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
-
Vertex Reports Second-Quarter 2021 Financial Results
7/29/2021
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2021 and raised full-year 2021 guidance for product revenues to $7.2 to $7.4B.
-
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
6/11/2021
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment.
-
Shares of Vertex fell more than 13% in premarket trading after it announced that it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study.
-
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
6/9/2021
Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration approved expanded use of TRIKAFTA® to include children with cystic fibrosis ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation in the CFTR gene that is responsive to TRIKAFTA based on in vitro data.
-
June is turning out to be a busy month for PDUFA dates for the U.S. Food and Drug Administration. Here’s a look at this week’s dates.